Endometrial Cancer

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about treatment options for advanced recurrent endometrial cancer.

  Healio spoke to Emma Rossi, MD, gynecological oncologist at Duke Cancer Center, about recent advancements in endometrial cancer.

The FDA announced several regulatory actions.

Identification of inherited genetic mutations that elevate cancer risk and may be susceptible to targeted therapies has transformed oncology care.

The FDA approved dostarlimab in combination with chemotherapy for certain women with endometrial cancer.

Selinexor maintenance after systemic therapy extended median PFS more than four times longer than placebo for women with advanced or recurrent TP53 wild-type endometrial cancer, according to phase 3 study results.

Among women with stress urinary incontinence and endometrial intraepithelial neoplasia or early-stage cancer, concomitant surgeries for both conditions did not improve quality of life compared with cancer surgery alone, researchers reported.

The FDA announced several regulatory actions the past few weeks.

CHICAGO — Assessment of RUBY trial outcomes by blinded independent central review confirmed the benefits of adding dostarlimab to chemotherapy for women with primary advanced or recurrent endometrial cancer.

Metabolically healthy and unhealthy obesity appeared associated with increased risk for various obesity-associated cancer types, according to study results presented at European Congress on Obesity.